All In Biotech

Investigational drug · Phase 2

COH04S1

Also called: GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia.

Phase 2

Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

3

Any phase or sponsor naming "COH04S1"

First trial start

2020

Nov 19, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "COH04S1", any sponsor or status.

Conditions studied

As listed on its trial records.

  • COVID-19 Infection
  • Hematopoietic and Lymphoid System Neoplasm
  • Leukemia
  • Lymphoma
  • Plasma Cell Myeloma

Approved drugs for the same conditions: COVID-19 · Oncology · Hematology and blood cancers · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "COH04S1" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 12 on PubMed

Also in development for COVID-19 Infection

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.